Amgen Company Profile (NASDAQ:AMGN)

About Amgen

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AMGN
  • CUSIP: 03116210
Key Metrics:
  • Previous Close: $171.63
  • 50 Day Moving Average: $172.00
  • 200 Day Moving Average: $160.83
  • 52-Week Range: $135.64 - $176.85
  • Trailing P/E Ratio: 17.37
  • Foreward P/E Ratio: 13.84
  • P/E Growth: 1.91
  • Market Cap: $127.00B
  • Outstanding Shares: 748,360,000
  • Beta: 0.87
  • Net Margins: 33.07%
  • Return on Equity: 29.30%
  • Return on Assets: 11.45%
  • Debt-to-Equity Ratio: 0.93%
  • Current Ratio: 3.97%
  • Quick Ratio: 3.72%
Additional Links:
Companies Related to Amgen:

Analyst Ratings

Consensus Ratings for Amgen (NASDAQ:AMGN) (?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $184.50 (8.71% upside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
DateFirmActionRatingPrice TargetDetails
9/28/2016Jefferies GroupReiterated RatingBuyView Rating Details
9/28/2016Citigroup Inc.Lower Price TargetNeutral$175.00 -> $172.00View Rating Details
9/28/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
9/27/2016Goldman Sachs Group Inc.Reiterated RatingBuy$204.00 -> $206.00View Rating Details
9/22/2016BMO Capital MarketsReiterated RatingOutperform$190.00View Rating Details
9/19/2016Cowen and CompanyReiterated RatingBuyView Rating Details
9/17/2016Leerink SwannReiterated RatingHoldView Rating Details
9/17/2016Credit Suisse Group AGSet Price TargetBuy$206.00View Rating Details
9/15/2016Piper Jaffray Cos.Set Price TargetBuy$193.00View Rating Details
8/26/2016Morgan StanleyReiterated RatingOverweight$199.00 -> $198.00View Rating Details
8/26/2016GabelliInitiated CoverageHoldView Rating Details
8/26/2016Robert W. BairdReiterated RatingOutperform$157.00View Rating Details
8/5/2016ArgusReiterated RatingBuy$185.00 -> $195.00View Rating Details
7/28/2016Barclays PLCReiterated RatingEqual Weight$185.00View Rating Details
7/13/2016Bank of America Corp.Reiterated RatingHold$182.00View Rating Details
6/29/2016Sanford C. BernsteinInitiated CoverageMarket Perform$161.00View Rating Details
5/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00View Rating Details
1/22/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00View Rating Details
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00View Rating Details
8/31/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
8/17/2015Deutsche Bank AGReiterated RatingBuy$195.00View Rating Details
(Data available from 9/29/2014 forward)


Earnings History for Amgen (NASDAQ:AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.10$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amgen (NASDAQ:AMGN)
Current Year EPS Consensus Estimate: $11.34 EPS
Next Year EPS Consensus Estimate: $12.26 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$2.48$2.84$2.61
Q2 20163$2.66$2.94$2.77
Q3 20163$2.72$3.03$2.84
Q4 20163$2.64$3.03$2.82
Q1 20171$2.81$2.81$2.81
Q2 20171$2.84$2.84$2.84
Q3 20171$2.89$2.89$2.89
Q4 20171$2.97$2.97$2.97
(Data provided by Zacks Investment Research)


Current Dividend Information for Amgen (NASDAQ:AMGN)
Annual Dividend:$4.00
Dividend Yield:2.36%
Payout Ratio:40.90% (Based on Trailing 12 Months of Earnings)
35.27% (Based on Current Year Consensus EPS Estimate)
32.63% (Based on Next Year Consensus EPS Estimate)

Dividend History for Amgen (NASDAQ:AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Amgen (NASDAQ:AMGN)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 79.15%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Amgen (NASDAQ:AMGN)
DateHeadline logoArrowhead's Landmark Deal With Amgen Sends Shares Shooting Higher (NASDAQ:AMGN) - September 29 at 1:15 PM logoArrowhead Pharma inks two agreements with Amgen for RNAi candidates in cardiovascular disease; shares up 21% premarket (NASDAQ:AMGN) - September 29 at 8:19 AM
News IconAmgen Inc. (AMGN) stock falls, "Buy" rating reiterated at Goldman Sachs Group Inc. - BNB Daily (blog) (NASDAQ:AMGN) - September 29 at 8:14 AM logo3 Reasons Not to Lose Faith in Amgen, Inc. (AMGN) - (NASDAQ:AMGN) - September 29 at 8:14 AM logoAmgen and Arrowhead Pharma agree 2 cardiovascular collaborations (NASDAQ:AMGN) - September 29 at 8:14 AM logoAmgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations (NASDAQ:AMGN) - September 29 at 8:14 AM
News IconView the Stunning Stock of the Day - Amgen Inc. (NASDAQ:AMGN) - Hot Stocks Point (NASDAQ:AMGN) - September 28 at 3:25 PM logoFour Stellar Stocks to Beat the Biotech Slump (NASDAQ:AMGN) - September 28 at 3:25 PM logo3 Reasons Not to Lose Faith in Amgen, Inc. (AMGN) (NASDAQ:AMGN) - September 28 at 12:49 PM logoAmgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News (NASDAQ:AMGN) - September 28 at 10:43 AM logoAmgen's Biosimilar Gets FDA Approval (AMGN, ABBV) | Investopedia - Investopedia (NASDAQ:AMGN) - September 28 at 8:14 AM logoAmgen's Osteoporosis Drug Crosses a Hurdle (AMGN) | Investopedia - Investopedia (NASDAQ:AMGN) - September 28 at 8:14 AM logoAmgen, Inc. Kyprolis Fails To Show PFS Benefit - TCC (NASDAQ:AMGN) - September 28 at 8:14 AM logoAmgen's Osteoporosis Drug Crosses a Hurdle (AMGN) (NASDAQ:AMGN) - September 28 at 8:14 AM logoWhitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter (NASDAQ:AMGN) - September 28 at 8:14 AM logoAmgen's Biosimilar Gets FDA Approval (AMGN, ABBV) (NASDAQ:AMGN) - September 28 at 8:14 AM logoAmgen Announces Top-line Results from Phase III Kyprolis® (Carfilzomib) CLARION Study in Newly Diagnosed Multiple Myeloma Patients (57.2KB) (NASDAQ:AMGN) - September 28 at 8:14 AM logoAmgen's Multiple Myeloma Drug Kyprolis Fails in Phase III (NASDAQ:AMGN) - September 28 at 8:14 AM
News IconTime To Put On The Watch List? - Amgen Inc. (NASDAQ:AMGN), ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) - The Voice Registrar (NASDAQ:AMGN) - September 27 at 3:27 PM logoBuzz Stocks: Amgen, Inc., Kite Pharma Inc, and WebMD Health Corp. - Schaeffers Research (blog) (NASDAQ:AMGN) - September 27 at 3:27 PM logoAmgen's Kyprolis Clarion Call Falls On Deaf Ears - Seeking Alpha (NASDAQ:AMGN) - September 27 at 3:27 PM logoAmgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade (NASDAQ:AMGN) - September 27 at 3:27 PM logoShares of Ligand plunge 13% after Amgen drug misses study goal (NASDAQ:AMGN) - September 27 at 3:27 PM logoLigand Pharma down 9% on failure of Amgen's Phase 3 Kyprolis study (NASDAQ:AMGN) - September 27 at 12:30 PM logoUPDATE 3-Amgen's multiple myeloma drug falls short in new-patient study (NASDAQ:AMGN) - September 27 at 11:27 AM logoAmgen says cancer treatment missed late-stage endpoint (NASDAQ:AMGN) - September 27 at 8:59 AM logoAmgen's Venture Funding Initiative (AMGN) - Investopedia (NASDAQ:AMGN) - September 27 at 5:58 AM logoAmgen's multiple myeloma drug falls short in late stage study (NASDAQ:AMGN) - September 27 at 5:40 AM logoAmgen’s Venture Funding Initiative (AMGN) (NASDAQ:AMGN) - September 26 at 8:26 PM logoAmgen, Inc. (AMGN) Starting a New Era of Biosimilars (NASDAQ:AMGN) - September 26 at 8:26 PM logoAnalysts Set EPS Target of $2.79 For Amgen Inc. (NASDAQ:AMGN) (NASDAQ:AMGN) - September 26 at 8:26 PM logoAmgen Opens Nomination Process For LabCentral Residency (NASDAQ:AMGN) - September 26 at 8:26 PM logoAnalysts Set EPS Target of $2.79 For Amgen Inc. (NASDAQ:AMGN) - Stocks Daily (NASDAQ:AMGN) - September 26 at 3:26 PM
News IconIs Amgen Inc.(NASDAQ: AMGN), a large market cap stock a smart buy? - The Daily Leicester (NASDAQ:AMGN) - September 26 at 3:26 PM
News IconTime To Put On The Watch List? - Amgen Inc. (NASDAQ:AMGN), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - The Voice Registrar (NASDAQ:AMGN) - September 26 at 3:26 PM logoAmgen's Biosimilar of Abbvie's Humira Gets FDA Approval (NASDAQ:AMGN) - September 26 at 8:09 AM logo3 Trades to Blaze a Trail Higher in Amgen (NASDAQ:AMGN) - September 26 at 8:09 AM logoAmgen, Inc. (AMGN) Starting a New Era of Biosimilars - TCC (NASDAQ:AMGN) - September 24 at 3:24 PM
News IconAmgen Inc. (NASDAQ:AMGN) from Biotechnology – Todays Top Gains (NASDAQ:AMGN) - September 24 at 8:47 AM
News IconFDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update (NASDAQ:AMGN) - September 24 at 8:47 AM
News IconFDA Approves Amgen's Humira Biosimilar - San Fernando Valley Business Journal (NASDAQ:AMGN) - September 23 at 9:22 PM logoBRIEF-FDA approves Amgen's Amjevita (Adalimumab-Atto) (NASDAQ:AMGN) - September 23 at 6:54 PM logoUPDATE 1-U.S. FDA approves Amgen's copy of AbbVie arthritis drug Humira (NASDAQ:AMGN) - September 23 at 5:36 PM
News IconActivity Reported By SEC: As Amgen INC (AMGN) Share Price Declined, Profund Advisors LLC Has Lowered by ... - Chester News (NASDAQ:AMGN) - September 23 at 3:52 PM
News IconTime To Put On The Watch List? - Amgen Inc. (NASDAQ:AMGN), Juno Therapeutics Inc. (NASDAQ:JUNO) - The Voice Registrar (NASDAQ:AMGN) - September 23 at 3:52 PM
News IconBiotech Stocks Worth a Closer Look: Amgen Inc. (NASDAQ:AMGN), Gilead Sciences Inc. (NASDAQ:GILD) - The Voice Registrar (NASDAQ:AMGN) - September 23 at 8:17 AM logoCramer Remix: Outrunning trading algorithms with the clic... (NASDAQ:AMGN) - September 23 at 8:17 AM logo[$$] Biotech Is Cheaper Than Big Pharma: What to Buy (NASDAQ:AMGN) - September 23 at 8:17 AM
News IconToday's Top Gainers in the Market Amgen Inc. (NASDAQ:AMGN) from Healthcare - The Daily Leicester (NASDAQ:AMGN) - September 22 at 3:26 PM
News IconTime To Put On The Watch List? - Amgen Inc. (NASDAQ:AMGN), CorMedix, Inc. (NYSEMKT:CRMD) - The Voice Registrar (NASDAQ:AMGN) - September 22 at 9:20 AM


Amgen (NASDAQ:AMGN) Chart for Thursday, September, 29, 2016

Last Updated on 9/29/2016 by Staff